


Dr. Balaji Ramachandran

Senior Principal Scientist, Syngene International Limited



Balaji Ramachandran is a pharmacologist with 17 years of research experience in Oncology Drug Discovery & Research Platform. He is currently working as a senior principal scientist at Syngene leading the in vivo oncology group and managing anticancer therapeutic programs involving Xenograft & Syngeneic tumor models, Immuno-Oncology, Humanized Mice Platform, Patient derived xenografts (PDX), Translational Research (mouse co-clinical trials), PK/PD correlation and Preclinical In-vivo Small Animal Imaging. His research areas have expanded from the basic core research, including conventional animal models, to the current focus on human primary tumors and cancer stem cells, with the major goals of significantly improving clinical predictiveness & therapeutic efficacy of drugs. In his former role, he has significantly contributed to the preclinical development of novel epigenetic and signal transduction pathway inhibitors in oncology space. He has published 18 Scientific publications, 6 International patents (USPTO) as co-inventor, 2 Indian Patents, and 13 abstracts. He has done his doctoral training in Pharmacology/Biotechnology from Dr.MGR University, Chennai, India and Master of Pharmacy in pharmacology from Tamil Nadu Dr. MGR medical university, Chennai, India and has done his MBA from IIPM, Lucknow, India. He is an active member in American Association for Cancer Research (AACR) and in European Association of Cancer Research (EACR).